Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:05:06.463Z.
Calculation as of: 2026-10-06T18:05:06.463Z.
Quote observation: 2026-10-06T18:00:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a212b8c45fb170636f79061a8993a9d466e21915543081357b5b59dac86f944c
PE RATIO
N/A
Market Cap
$302.90M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avita Medical Inc. (RCEL) | $318.87M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $318.77M | 2.89 | 2.74 | 2.74 | 27.61 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $321.49M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.74M | N/A | 16.56 | 19.39 | 19.39 |
| Cabaletta Bio, Inc. (CABA)vs › | $321.77M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $312.35M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $325.68M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $302.90M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $301.99M | N/A | 396.83 | 396.83 | 396.83 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.39M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute